Cargando…

The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases

Neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS), currently affect more than 6 million people in the United States. Unfortunately, there are no treatments that slow or prevent disease developm...

Descripción completa

Detalles Bibliográficos
Autor principal: Maher, Pamela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627573/
https://www.ncbi.nlm.nih.gov/pubmed/31234550
http://dx.doi.org/10.3390/ijms20123056
_version_ 1783434768114778112
author Maher, Pamela
author_facet Maher, Pamela
author_sort Maher, Pamela
collection PubMed
description Neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS), currently affect more than 6 million people in the United States. Unfortunately, there are no treatments that slow or prevent disease development and progression. Regardless of the underlying cause of the disorder, age is the strongest risk factor for developing these maladies, suggesting that changes that occur in the aging brain put it at increased risk for neurodegenerative disease development. Moreover, since there are a number of different changes that occur in the aging brain, it is unlikely that targeting a single change is going to be effective for disease treatment. Thus, compounds that have multiple biological activities that can impact the various age-associated changes in the brain that contribute to neurodegenerative disease development and progression are needed. The plant-derived flavonoids have a wide range of activities that could make them particularly effective for blocking the age-associated toxicity pathways associated with neurodegenerative diseases. In this review, the evidence for beneficial effects of multiple flavonoids in models of AD, PD, HD, and ALS is presented and common mechanisms of action are identified. Overall, the preclinical data strongly support further investigation of specific flavonoids for the treatment of neurodegenerative diseases.
format Online
Article
Text
id pubmed-6627573
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66275732019-07-23 The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases Maher, Pamela Int J Mol Sci Review Neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS), currently affect more than 6 million people in the United States. Unfortunately, there are no treatments that slow or prevent disease development and progression. Regardless of the underlying cause of the disorder, age is the strongest risk factor for developing these maladies, suggesting that changes that occur in the aging brain put it at increased risk for neurodegenerative disease development. Moreover, since there are a number of different changes that occur in the aging brain, it is unlikely that targeting a single change is going to be effective for disease treatment. Thus, compounds that have multiple biological activities that can impact the various age-associated changes in the brain that contribute to neurodegenerative disease development and progression are needed. The plant-derived flavonoids have a wide range of activities that could make them particularly effective for blocking the age-associated toxicity pathways associated with neurodegenerative diseases. In this review, the evidence for beneficial effects of multiple flavonoids in models of AD, PD, HD, and ALS is presented and common mechanisms of action are identified. Overall, the preclinical data strongly support further investigation of specific flavonoids for the treatment of neurodegenerative diseases. MDPI 2019-06-22 /pmc/articles/PMC6627573/ /pubmed/31234550 http://dx.doi.org/10.3390/ijms20123056 Text en © 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Maher, Pamela
The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases
title The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases
title_full The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases
title_fullStr The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases
title_full_unstemmed The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases
title_short The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases
title_sort potential of flavonoids for the treatment of neurodegenerative diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627573/
https://www.ncbi.nlm.nih.gov/pubmed/31234550
http://dx.doi.org/10.3390/ijms20123056
work_keys_str_mv AT maherpamela thepotentialofflavonoidsforthetreatmentofneurodegenerativediseases
AT maherpamela potentialofflavonoidsforthetreatmentofneurodegenerativediseases